Company news
Elicera Therapeutics Ab (OMXSTO:ELIC) news
Elicera Therapeutics Ab news releases on 6ix. Latest, Jun 1, 2026: Elicera announces outcome of the rights issue
Press releases & updates
Elicera announces outcome of the rights issue
June 1, 2026
Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved
May 25, 2026
Elicera publishes information document regarding the rights issue
May 11, 2026
Elicera Therapeutics carries out a rights issue of approximately SEK 73 million
April 21, 2026
Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate
March 11, 2026
Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients
March 6, 2026
Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway
February 27, 2026
Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study
February 11, 2026
Elicera Therapeutics presents positive phase I/IIa data for ELC-100
January 9, 2026
Elicera Therapeutics announces final data from its Phase I/IIa trial demonstrating a favorable safety profile and promising efficacy signals of oncolytic virus ELC-100 in neuroendocrine tumors
January 9, 2026
Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ)
December 23, 2025
Elicera Therapeutics announces that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research
November 13, 2025